Council Decision (EU) 2026/575 of 5 March 2026 on the position to be taken on behalf of the European Union in the 69th session of the Commission on Narcotic Drugs on the scheduling of substances under the Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, and the Convention on Psychotropic Substances of 1971

• CELEX: Decision (EU) 2026/575
• Articles: 4

Article 1

The position to be taken on behalf of the Union in the 69th session of the Commission on Narcotic Drugs (CND), from 9 to 13 March 2026, as regards the adoption of decisions on the addition of substances to the schedules to the United Nations Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, and to the United Nations Convention on Psychotropic Substances of 1971, is set out in the Annex to this Decision.

Article 2

The position referred to in Article 1 shall be expressed by the Member States that are members of the CND, acting jointly in the interest of the Union.

Article 3

This Decision is addressed to the Member States in accordance with the Treaties.

Schedules & Appendices

ANNEX

ANNEX

Position to be taken by the Member States which are members of the Commission on Narcotic Drugs, acting jointly in the interest of the Union, during the 69th session of the Commission on Narcotic Drugs from 9 to 13 March 2026 on the scheduling of substances:

(1)

N -pyrrolidino isotonitazene (Isotonitazepyne) (IUPAC name: 5-nitro-2-({4-[(propan-2-yl)oxy]phenyl}methyl)-1-[2-(pyrrolidin-1-yl)ethyl]-1 H -1,3-benzimidazole) is to be included in Schedule I to the Convention on Narcotic Drugs;

(2)

N -desethyl etonitazene (IUPAC name: 2-[2-[(4-ethoxyphenyl)methyl]-5-nitro-benzimidazol-1-yl]- N -ethyl-ethanamine) is to be included in Schedule I to the Convention on Narcotic Drugs;

(3)

MDMB-FUBINACA (IUPAC name: methyl 2-[[1-[(4-fluorophenyl)methyl]indazole-3-carbonyl]amino]-3,3-dimethyl-butanoate) is to be included in Schedule II to the Convention on Psychotropic Substances.